189 related articles for article (PubMed ID: 30160782)
21. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
23. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
Lee MH; Huang YH; Chen HY; Khor SS; Chang YH; Lin YJ; Jen CL; Lu SN; Yang HI; Nishida N; Sugiyama M; Mizokami M; Yuan Y; L'Italien G; Tokunaga K; Chen CJ;
Hepatology; 2018 Feb; 67(2):651-661. PubMed ID: 28921602
[TBL] [Abstract][Full Text] [Related]
24. Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese.
Shi Y; Zhai W; Wang B; Zhao D; Jin H; Wang Y; Zhang J; An H; Fu Z; Zhao K; Lu C
Oncotarget; 2016 Dec; 7(49):80935-80942. PubMed ID: 27821814
[TBL] [Abstract][Full Text] [Related]
25. The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population.
Deng Y; Li P; Liu W; Pu R; Yang F; Song J; Yin J; Han X; Li C; Zhao J; Wang H; Cao G
J Viral Hepat; 2020 Nov; 27(11):1150-1161. PubMed ID: 32568442
[TBL] [Abstract][Full Text] [Related]
26. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Lin CC; Bair MJ; Liu CY; Lin ZY; Chen CJ; Chen MJ; Chu CH; Wang HY; Shih SC; Wang TE
Medicine (Baltimore); 2019 Jan; 98(1):e13818. PubMed ID: 30608393
[TBL] [Abstract][Full Text] [Related]
27. Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci in a Chinese population.
Chen K; Shi W; Xin Z; Wang H; Zhu X; Wu X; Li Z; Li H; Liu Y
PLoS One; 2013; 8(10):e77315. PubMed ID: 24204805
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis.
Chen YC; Peng CY; Jeng WJ; Chien RN; Liaw YF
Aliment Pharmacol Ther; 2015 Nov; 42(10):1182-91. PubMed ID: 26381928
[TBL] [Abstract][Full Text] [Related]
29. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
[TBL] [Abstract][Full Text] [Related]
30. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
31. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.
Jeng JE; Tsai JF; Chuang LY; Ho MS; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Chang JG
Neoplasia; 2007 Nov; 9(11):987-92. PubMed ID: 18030367
[TBL] [Abstract][Full Text] [Related]
33. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development.
Hu L; Zhai X; Liu J; Chu M; Pan S; Jiang J; Zhang Y; Wang H; Chen J; Shen H; Hu Z
Hepatology; 2012 May; 55(5):1426-31. PubMed ID: 22105689
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
35. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
36. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P; Sonneveld MJ; Zoutendijk R; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Reijnders JG; Oo Y; Petersen J; van Bömmel F; de Knegt RJ; Santantonio T; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen B; Janssen HL;
Gut; 2015 Aug; 64(8):1289-95. PubMed ID: 25011935
[TBL] [Abstract][Full Text] [Related]
37. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
38. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphism of HLA-DQ confers susceptibility to hepatitis B virus-related hepatocellular carcinoma: a case-control study in Han population in China.
Gao X; Liu W; Zhang X; Tang L; Wang L; Yan L; Yang H; Li T; Yang L; Ma N; Liu D
Tumour Biol; 2016 Sep; 37(9):12103-12111. PubMed ID: 27209411
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir.
Kim MN; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Ahn SH
J Clin Gastroenterol; 2014 Mar; 48(3):272-8. PubMed ID: 23811938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
